Clinical Context
A pediatric patient with a genetically confirmed diagnosis of spinal muscular atrophy (SMA) type 1 is scheduled for a single-dose intravenous gene replacement therapy using onasemnogene abeparvovec-xioi. The clinical workflow begins with multidisciplinary pre-treatment evaluation: neurology confirms SMA with biallelic SMN1 deletion, baseline laboratory testing (CBC, liver panel, coagulation studies), and anti-AAV9 antibody titer assessment. A weight-based dose calculation is performed to confirm the total vector genomes do not exceed the single-treatment vial limit described by J3399. Pre-medications (for example, corticosteroids) are prescribed to mitigate transaminase elevations and immune responses, and caregivers receive education on monitoring and emergency contacts.
On the day of service the child is admitted to an outpatient infusion center or inpatient pediatric unit depending on institutional protocol and clinical status. An infusion nurse and pediatric anesthesiology or sedation team establish IV access, verify patient identity and informed consent, and administer the intravenous infusion over the recommended time with continuous monitoring of vital signs. Liver enzymes and platelets are monitored post-infusion; corticosteroid taper is followed per protocol. Follow-up visits include liver function monitoring, clinical neurology assessments, and documentation of adverse events. Billing uses J3399 for the onasemnogene abeparvovec-xioi administration, with potential addition of appropriate modifiers to indicate unusual circumstances such as distinct procedural services, service reductions, or anesthesia involvement.